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INTRODUCTION: Monitoring and modifying physicians’
prescribing behavior through prescription tracking is
integral to pharmaceutical marketing. Health informa-
tion organizations (HIOs) combine prescription infor-
mation purchased from pharmacies with anonymized
patient medical records purchased from health insur-
ance companies to determine which drugs individual
physicians prefer for specific diagnoses and patient
populations. This information is used to tailor market-
ing strategies to individual physicians and to assess the
effect of promotions on prescribing behavior.
DISCUSSION: The American Medical Association (AMA)
created the Prescription Data Restriction Plan in an
attempt to address both the privacy concerns of physi-
cians and industry concerns that legislation could
compromise the availability of prescribing data. Howev-
er, the PDRP only prohibits sales representatives and
their immediate supervisors from accessing the most
detailed reports. Less than 2% of US physicians have
registered for the PDRP, and those who have signed up
are not the physicians who are targeted for marketing.
CONCLUSION: Although it has been argued that pre-
scription tracking benefits public health, data gathered
by HIOs is designed for marketing drugs. These data are
sequestered by industry and are not generally available
for genuine public health purposes.
KEY WORDS: prescription tracking; public health; pharmaceutical
companies; physicians; health information organizations; prescribing
behavior; pharmaceutical marketing; patient-level data.
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P
harmaceutical companies track prescriptions to develop
and evaluate general marketing efforts and to tailor sales
pitches to individual physicians.
1 The information is also used
to allocate samples, to design continuing medical education
programs and direct-to-consumer campaigns, and to evaluate
the effects of specific promotions on sales. Internally, pharma-
ceutical companies use prescription tracking to identify phy-
sicians to target, to delineate sales force territories, and to
evaluate and compensate sales representatives who receive
bonuses based on drug sales in their area.
2,3
Prescription information is collected by health information
organizations (HIOs), which have monitored prescriptions via
surveillance technologies since the 1950s.
4 Access to informa-
tion regarding the prescriptions of individual physicians has
been available since 1989.
5 HIOs, also known as data-mining
companies, act as brokers of this information, which they
package from different sources to create detailed prescribing
portraits of each physician. IMS Health is the largest HIO;
others include Dendrite, Verispan, and Wolters Kluwer.
6
Pharmacies, the primary source of prescribing data, sell
patients’ prescription records that include the date, medica-
tion name, dose, and directions. Specific unique numbers are
substituted for patient names. Prescribers are identified by
number (usually state license or Drug Enforcement Adminis-
tration numbers). IMS obtains records on about 70% of
prescriptions filled in community pharmacies.
6 Prescription
information is also obtained from pharmacy benefit managers
and wholesalers.
3
In the United States, HIOs are able to reassociate physician
identifiers withphysician namesbypurchasing informationfrom
the American Medical Association (AMA), which maintains the
Physician’s Masterfile, a database that contains demographic
information on all U.S. physicians.
6 Currently, the Masterfile
includes approximately 900,000 M.D.s and D.O.s in the United
States.
7AccordingtoacompanythatlicensesMasterfiledata,the
AMA also receives “student information from medical schools,
residency information from residency program directors, and
practice information from over 2,100 different resources includ-
ing medical organizations, institutions and government agen-
cies.”
8 The AMA has sold doctors’ demographic data to the
pharmaceutical industry continuously since the 1940s.
4
Incontrast,Canada,Europe,andmanyothercountriesdonot
allow industry access to information on each physician’sp r e -
scriptions. Prescribing data for groups of physicians (known as
“bricks”) are available, but not for individual physicians.
2
In the U.S., not only are individual physicians’ prescriptions
minutely monitored, but so are their patients’ medical records.
Although patient names are not included, information gathered
onindividualsmayincludeage,sex,geographiclocation,medical
conditions, hospitalizations, laboratory tests, insurance copays,
and medication use.
9 Although detailed information is tracked
on individuals over time, this commercial use of medical records
complies with the Health Insurance Portability and Accountabil-
ity Act (HIPAA), a federal statute that provides some medical
privacy protections, because patient names are not included.
Instead, unique numbers identify each individual.
9
PharMetrics, a unit of IMS, has a database that “contains >2
[billion] health care events including the complete set of phar-
macy and medical claims of >55 million Americans.”
10 “Anon-
ymized patient-level data” refines industry knowledge of
physicians’ prescribing behavior by revealing “first- and second-
line usage, diagnosis, compliance/persistency, and referral
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1277patterns.”
11 Patient-level data “can help marketers understand
which strategy will have the greatest effects on sales.”
11
Inother words, the linkage of medical claims with prescription
data allows HIOs to offer pharmaceutical companies detailed
i n f o r m a t i o no ne v e r yp h y s i c i a n ’s referral networks, patients, and
preferred treatments for specific diagnoses in specific patient
subpopulations. These data, usually updated on a weekly basis,
allow ongoing analyses of how a physician’s prescribing behavior
responds to personally tailored marketing strategies.
THE PDRP
In recent years, prescription tracking has become a controver-
sial issue among physicians. Several state legislatures have
introduced bills restricting prescription tracking. The AMA met
with industry and surveyed physicians, finding that although
two-thirds of physicians opposed the availability of prescribing
data to drug representatives, 77% of those would have their
concerns alleviated if doctors could choose to protect their
individual prescribing information.
3
In response to industry and physician concerns, the AMA
created the Prescription Data Restriction Plan (PDRP). Interested
physicians visit a website (http://www.ama-assn.org/go/
prescribingdata) and fill out a form requesting that their
prescribing data be withheld from pharmaceutical sales repre-
sentatives. To activate one’s PDRP rights online, a physician
must check off or provide a reason for opting out and accept the
vaguely ominous statement that, “Some of the information
provided may be shared with entities outside the AMA in order
to register and/or follow up on your concern.” Requests expire
3yearsfromwhenthephysiciansignsup,andrequestsmaytake
6 months to take effect because drug companies are required to
check the list quarterly and then have 90 days to restrict sales
representatives access to these data.
12
A pilot version of the PDRP was launched in California and
several other states in May 2006; the program officially
launched nationally in July 2006.
7
Few doctors know about the PDRP. Soon after the program
launched, a poll of 210 physicians found that only 18% were
aware of the program; more than half (53%) were interested in
signing up.
13
The AMA mailed no announcements to physicians because
studies have shown that “direct mail to physicians is very
inefficient,” according to the AMA’s Media Outreach Coordina-
tor,
7 who also noted that office staff often intercept physicians’
mail. Instead, the AMA placed ads or announcements in AMA
publications and several medical journals, and e-mailed
announcements to about 100,000 physicians, about 1,000 of
whom subsequently signed up for the PDRP.
7 By July 18,
2006, 2,900 of 800,000 practicing physicians had signed up
for the PDRP.
13 By May 2007, a year after the program began,
about 1% of active physicians (7,476) doctors had opted out.
14
By January 2008, almost 12,000 doctors (65% of whom are
not AMA members) have signed up.
15
Such low participation in the PDRP is predictable because
opt-out options “are designed to maximize participation while
preserving a patina of choice.”
16 Default choices are perceived
to be socially preferable, so opt-out options have resulted in
increased default participation in situations as diverse as
prenatal HIV testing, 401(k) savings plans, and medical
journal reviewing.
16
In its current form, the PDRP withholds some information
from some industry representatives some of the time. Individ-
ual prescribing information is withheld only from pharmaceu-
tical representatives and their immediate supervisors. All other
employees retain full access to all the individual-specific
prescribing information. As an industry article puts it, “The
information available to the ‘home office’ will not change,
regardless of physician enrollment in PDRP. This program will
not affect headquarter business systems.”
17 The most relevant
information is still available to pharmaceutical representatives
because the PDRP exempts information on “(a) deciles at the
market or therapeutic class level, (b) segmented data that are
not likely to reveal the actual or estimated activity of an
individual physician, or (c) data on products ordered by
physicians from pharmaceutical companies.”
17
In other words, the PDRP does not restrict pharmaceutical
companies from seeing, analyzing, and using prescribing data
to promote specific drugs to the doctors who have opted out.
However, the pharmaceutical representatives and managers
are still provided the information that Dr. X is in the top 10% of
doctors in terms of prescribing volume for antidepressants; in
the top 20% for antibiotics; and is an “early adopter” of drugs.
Pharmaceutical representatives enjoy full access to drug-
specific details on chemotherapy or any other drugs dispensed
or administered in physicians’ offices. An industry article notes
that that although the PDRP “limits reps and their supervisors
from accessing data on some physicians, it nonetheless enable
companies to continue to run essential business applications
that rely on prescriber data.”
17
Whereas a massive physician sign-up of high prescribers for
the PDRP would inconvenience pharmaceutical companies,
“the opt-outs to date are generally lower-prescribing physi-
cians, with 72% in the market-five decile or lower.”
3 Doctors in
the bottom half of prescribers are not targeted for marketing
anyway.
AN ALTERNATIVE TO LAW
In 2006, New Hampshire passed a law banning commercial sale
of prescribing data and was promptly sued by IMS and Verispan.
On April 30, 2007, a federal judge ruled the New Hampshire law
unconstitutional on the grounds that it restricts commercial free
speech.
18 The state plans to appeal the decision.
Other states are considering similar bills, but the decision in
New Hampshire and the availability of the PDRP has had an
effect. A preliminary injunction was granted to prevent en-
forcement of a Maine law (which is also being appealed), and
Vermont is now modifying a law that it passed.
15 The
availability of the PDRP was key to a 2006 decision not to
reintroduce California Assembly Bill 262 (narrowly defeated in
2004), which would have severely restricted the sale and use of
prescription data.
5
An industry publication explains, “Pharmaceutical manu-
facturers need to make the PDRP work, since the alternative,
government legislation, is not in anyone’s best interest.
Without PDRP, long-term access to physician-level data within
the healthcare system is called into question.”
5 The AMA’s
PDRP brochure states that the program “responsibly honors
the opinions of all physicians—and provides a more reasonable
alternative to a “one-size-fits-all” legislative ban that ignores
vital aspects of prescribing data use.”
19
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article coauthored by AMA and IMS employees, which states,
“The rules allow the industry to retain access to prescribing
data for most purposes, but they require companies to police
their own sales forces. If they succeed, legislators will turn
their attention elsewhere, and the industry can hang onto one
of its most valuable data sources.”
17
RISKS AND BENEFITS OF RX TRACKING
Pharmaceutical interests argue that unrestricted access to
prescribing data saves lives, money, and physicians’ time. The
Pharmaceutical Research and Manufacturers of America
(PhRMA) has argued that prescriber data are needed to send
out communications informing doctors of drug recalls and
serious adverse effects.
20 However, when the FDA orders a
recall or mandates a new black box warning on a drug, the
manufacturer is usually required to send a “Dear Health Care
Provider” letter to all U.S. prescribers, not just to those who
recently prescribed the drug.
PhRMA also argues that, “Access to prescriber data allows
pharmaceutical companies to target necessary prescription
information to physicians which helps avoid a saturation of less
relevant information to a broader physician audience.”
20 An
industry article states that, “Prescribing data allow pharmaceu-
tical promotion to be relevant and specific, making the whole
process more cost-effective (and sparing physicians from being
bombarded with extraneous promotional materials and sales
calls)….”
17 Certainly, these data enable the identification of
physicians relevant and specific to drug sales. Sales calls and
promotional materials are preferentially showered on high-
prescribing physicians and others who affect market share.
1
TheAMA,intestimonyopposinglegislationtorestrictindustry
access to prescriber data, states that, “this information is critical
to improving the quality, safety, and efficacy of providing patient
care through evidence-based medical research.”
21
The AMA is misguided on this point. Researchers do not
need HIO data, which are too expensive for most individual
researchers to purchase anyway.
4 (IMS has occasionally
provided limited data to some researchers without cost or at
discount.
20 Anecdotally, free data are older data and do not
contain dates of service or other information routinely provided
to paying customers.)
Although HIOs claim that the FDA relies on their data, the
use of HIO data by the FDA for public health purposes is
trivial. According to IMS’ 2006 Annual Report, “Sales to the
pharmaceutical industry accounted for substantially all of our
revenue in 2006, 2005, and 2004.”
22
It bears noting that HIOs are not the only source of prescrip-
tion data. Medicare, Medicaid, the military, the Veteran’sA d m i n -
istration, and largehealthmaintenanceorganizations (HMOs) all
have databases of medical and prescription information that
have been extensively used by health services researchers.
Databases of large HMOs can be used to examine commercially
insured populations. The inclusion of race and ethnicity data
makes Medicaid ideal for researching health outcomes in diverse
populations (Medicaid covers 1 in 5 Americans, including 1 in 3
African Americans and 1 in 4 Latinos).
23
Government data may be the most reliable for research
purposes. One recent analysis found prescription data avail-
able from the Center for Medicaid and Medicare Services (CMS)
superior to Medicaid data available from a commercial ven-
dor.
24 The coverage of outpatient prescription drugs through
Medicare Part D will create a trove of prescription data on
elders for researchers.
Public health research rarely requires the identification of
individual physicians. HIOs package physicians’ names with
prescriptions and patient medical records to facilitate phar-
maceutical marketing efforts to manipulate individual pre-
scribing habits.
There is no obligation for HIOs to share information with
government regulators—even when such information affects
public health. For example, sluggish sales of a migraine drug
in 2003 led an unnamed company to hire IMS Health to
determine why.
25 IMS researchers hypothesized that lower-
than-forecasted sales of the migraine drug could be because of
decreased menopausal hormone use. Millions of women
stopped taking menopausal hormones in mid-2002 when the
Women’s Health Initiative showed that risks outweighed
benefits for the most popular estrogen–progestin regimen.
IMS examined the medical records of 41,403 women with
migraines and found that those who stopped hormone therapy
halved their use of migraine drug prescriptions. Women filled
an average of 2.94 prescriptions for migraine medication
during a 6-month period on hormone therapy compared with
an average of 1.49 prescriptions during a 6-month period after
they stopped hormones. More than half of the women (54%)
filled no migraine drug prescriptions in the 6 months after
quitting hormones.
25
This very large study, which definitively linked migraines
and hormone therapy, was never shared with physicians nor
published in the medical literature. It was mentioned, in a
publication directed exclusively at pharmaceutical marketers,
as an example of the services HIOs provide to pharmaceutical
companies. What other marketing studies with implications
for public health are hidden in industry files? Pharmaceutical
companies are required by law to report adverse events
associated with their products to the FDA. HIOs should also
be required to report adverse effects of therapies they study.
The commercial sale and use of prescriptions and medical
records compromises the privacy of individual prescribers and
patients, is not necessary for health services research, and
may well have adverse effects on public health. The purpose of
prescription tracking is to promote the use of the newest, most
expensive drugs, a practice that threatens rational prescribing.
Assessment of the benefits and harms of medications
should be a government function, implemented by researchers
without commercial ties, and conducted solely in the public
health interest. Public monies should be allocated to integrate
existing public sources of health data and expand accessibility
to researchers who will use these data in the interests of
patients rather than industry profits.
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